We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-14.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$9.59M
AUM Growth
-$434M
Cap. Flow
-$279M
Cap. Flow %
-2,907.54%
Top 10 Hldgs %
47.01%
Holding
85
New
15
Increased
1
Reduced
62
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.17M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.24M
3
BNTX icon
BioNTech
BNTX
+$588K
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$408K
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$180K

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$16.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$16.6M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.2M
4
PTCT icon
PTC Therapeutics
PTCT
+$14.4M
5
AMGN icon
Amgen
AMGN
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Miscellaneous 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
51
CRISPR Therapeutics
CRSP
$5.74B
$34.2K 0.36%
+2,078
New +$122K
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$32.5K 0.34%
1,470
-31,030
-95% -$1.41M
NVCR icon
53
NovoCure
NVCR
$2.09B
$32K 0.33%
+2,224
New +$168K
ICPT
54
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$32K 0.33%
+441
New +$7.06K
SNY icon
55
Sanofi
SNY
$107B
$31.5K 0.33%
1,576
-29,924
-95% -$1.59M
ASND icon
56
Ascendis Pharma A/S
ASND
$16.4B
$29.4K 0.31%
2,733
-26,667
-91% -$2.51M
BNTX icon
57
BioNTech
BNTX
$28B
$25.8K 0.27%
+3,847
New +$588K
XENE icon
58
Xenon Pharmaceuticals
XENE
$6B
$25.5K 0.27%
774
-24,726
-97% -$748K
NTLA icon
59
Intellia Therapeutics
NTLA
$1.84B
$24K 0.25%
1,242
-22,758
-95% -$1.16M
REGN icon
60
Regeneron Pharmaceuticals
REGN
$83.1B
$23.7K 0.25%
14,010
+1,910
+16% +$1.24M
BEAM icon
61
Beam Therapeutics
BEAM
$3.15B
$23.5K 0.25%
+910
New +$36.2K
AGIO icon
62
Agios Pharmaceuticals
AGIO
$2.05B
$21.5K 0.22%
476
-21,024
-98% -$475K
PTCT icon
63
PTC Therapeutics
PTCT
$5.99B
$21K 0.22%
842
-410,158
-100% -$14.4M
UTHR icon
64
United Therapeutics
UTHR
$22.7B
$20K 0.21%
4,713
-15,287
-76% -$3.11M
BPMC
65
DELISTED
Blueprint Medicines
BPMC
$19.5K 0.2%
985
-18,515
-95% -$1.08M
JAZZ icon
66
Jazz Pharmaceuticals
JAZZ
$16.3B
$17.2K 0.18%
2,683
-14,517
-84% -$2.23M
SWTX
67
DELISTED
SpringWorks Therapeutics
SWTX
$16.3K 0.17%
401
-15,899
-98% -$581K
PTGX icon
68
Protagonist Therapeutics
PTGX
$9.68B
$16.2K 0.17%
+128
New +$1.55K
ONC
69
BeOne Medicines Ltd
ONC
$42.1B
$15.7K 0.16%
2,542
-13,158
-84% -$2.06M
PRTA icon
70
Prothena Corp
PRTA
$465M
$15K 0.16%
407
-14,593
-97% -$427K
AXSM icon
71
Axsome Therapeutics
AXSM
$10.8B
$14K 0.15%
535
-13,465
-96% -$426K
KRTX
72
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$12.4K 0.13%
+1,567
New +$180K
ANAB icon
73
AnaptysBio
ANAB
$1.7B
$10K 0.1%
203
-9,797
-98% -$217K
RLMD icon
74
Relmada Therapeutics
RLMD
$482M
$10K 0.1%
190
-9,810
-98% -$214K
MDGL icon
75
Madrigal Pharmaceuticals
MDGL
$12.6B
$5.35K 0.06%
383
-4,967
-93% -$365K
1 2
3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2022 Portfolio in Review

As of Q2 2022, International Biotechnology Trust held 85 positions worth $9.59M, down 98% from $443M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $279M in Q2 2022, closing 7 positions and reducing 62 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $52K.

  • International Biotechnology Trust's largest Q2 2022 buy was Biogen: 10,606 shares worth $52K.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2022, an estimated $1.24M increase.
  • International Biotechnology Trust's biggest Q2 2022 reduction was Incyte, cutting an estimated $16.7M.
  • International Biotechnology Trust fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $9.29M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $9.59M portfolio in Q2 2022.
  • International Biotechnology Trust opened 15 new positions and closed 7 in Q2 2022.
  • International Biotechnology Trust's portfolio value fell 98% quarter-over-quarter to $9.59M.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.